Sp1057
APPLYING METABOLIC BIOMARKERS IN IRRITABLE BOWEL SYNDROME
Date
May 9, 2023
Explore related products in the following collection:
Society: AGA
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
DDW attendees will have the opportunity to learn about recent developments in biomarker-discovery for FGID/DGBI and Neurogastroenterology. Speakers will cover investigational and evolving biomarkers, practical utilization of biomarkers, and updates on biomarkers that are further down the pipeline and may be available for broader use in clinical practice and clinical research. Discuss novel and investigational biomarkers in functional gastrointestinal disorders (disorders of gut-brain interaction) Recognize currently available biomarkers and their potential applications in clinical practice, their strengths, and their limitations. Review the path to biomarker discovery and their role in enhancing patient care, highlighting challenges and future goals.
Presenter
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg
Tracks
Related Products
YOUNG VERSUS OLD GUT: DISTINCT AGE-RELATED CHARACTERISTICS IN IRRITABLE BOWEL SYNDROME
Ageing seems to have a beneficial effect on irritable bowel syndrome (IBS) (Sperber et al. Gastroenterology 2021), and the odds of developing IBS are lower when age is above 50 years (Lovell & Ford CGH 2012). Older age may also affect symptom reporting and quality of life…
INTRODUCTION
SOCIETY: AGA
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
